Biomega Group expands into Denmark to grow salmon peptide business

Image courtesy of Biomega Group

Biomega Group (Bergen, Norway) expanded its biorefining footprint by investing in a new greenfield site in Hirtshals, Denmark. The expansion will increase production capacity and support its plans to grow its new Biomega PURE salmon peptide business for the human health and nutrition market, and facilitate continued growth of its Salmigo range designed for premium petfood segments.

“Hirtshals, Denmark, is an important gateway for salmon into Europe with local volumes growing substantially year-on-year,” said Stig Petersen, CEO at Biomega, in a press release. “We are partnering with key local suppliers of high-quality fresh salmon parts. Biomega has received tremendous support from the local authorities, Hjørring municipality and Hirtshals Harbor administration for the development of the project. We are delighted to announce this strategic move, involving a double-digit million EUR investment in a brand-new facility, to support our growth plans in premium human and petfood nutrition applications.”

AMERRA Capital Management acquired Biomega in 2017 and invested additional capital for the execution of this project alongside Natixis Investment Managers affiliated asset manager, Mirova Natural Capital, and several members of the management team, including the original founders of Biomega.

“Biomega has demonstrated significant growth in the past couple of years, and we have expanded our team considerably as a result,” Petersen said. “The opportunities for our salmon peptides and oils are extensive and, alongside our sales in the premium petfood segment, we can now focus on human nutrition. We are working with a number of customers to commercialize health and nutrition concepts supported by consumer market trends and we’re excited by the opportunity that Hirtshals brings to expand our business.”